Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
https://www.zacks.com/stock/news/2289934/mustang-mbio-soars-477-on-data-from-rare-blood-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2289934
Jun 18, 2024 - Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
0
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
https://www.fool.com/investing/2024/06/12/a-life-expansion-revolution-is-coming-3-stocks-tha/?source=iedfolrf0000001
Jun 12, 2024 - The integration of AI and healthcare is well underway.
0
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2286932/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2286932
Jun 11, 2024 - Johnson & Johnson (JNJ) closed the most recent trading day at $146.76, moving -0.25% from the previous trading session.
0
Earnings Season Update and Analyst Reports for Broadcom, JNJ & Verizon
https://www.zacks.com/commentary/2286071/earnings-season-update-and-analyst-reports-for-broadcom-jnj-verizon?cid=CS-ZC-FT-research_daily-2286071
Jun 10, 2024 - Today's Research Daily features an earnings season update and new research reports on Broadcom (AVGO), Johnson & Johnson (JNJ) and Verizon (VZ), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Frequency Electronics, Inc. (FEIM).
0
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
https://www.zacks.com/stock/news/2285380/pharma-stock-roundup-lly-s-cfo-departs-abbv-azn-drugs-get-chmp-approval?cid=CS-ZC-FT-analyst_blog|stock_roundup-2285380
Jun 07, 2024 - Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
0
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
https://www.zacks.com/stock/news/2284729/halozyme-s-halo-enhanze-product-gets-new-patent-grant-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2284729
Jun 06, 2024 - Halozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of its ENHANZE rHuPH20 product in several EU countries until 2029.
0
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
https://www.zacks.com/stock/news/2283544/teva-stock-rises-135-in-a-year-what-s-driving-the-recovery?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2283544
Jun 04, 2024 - TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
0
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
https://www.zacks.com/stock/news/2281925/pharma-stock-roundup-jnj-mrk-m-a-deals-sny-rhhby-drugs-priority-review-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2281925
May 31, 2024 - J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
0
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2281695/johnson-johnson-jnj-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2281695
May 30, 2024 - Johnson & Johnson (JNJ) closed the most recent trading day at $145.28, moving +0.58% from the previous trading session.
0
Are You Looking for a High-Growth Dividend Stock?
https://www.zacks.com/stock/news/2280781/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2280781
May 29, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
0